Hydroxychloroquine Sulfate
NDC Package 42291-320-18

The code 42291-320-18 identifies a specific commercial package of 180 tablet in 1 bottle of Hydroxychloroquine Sulfate, labeled by Avkare, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 180 billable units per package. This is formulated for use and contains as the active substance.

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Avkare, Inc. on February 29, 2012. The current certification is valid through November 04, 2015.

Hydroxychloroquine is used to prevent or treat malaria caused by mosquito bites. The United States Center for Disease Control provides updated guidelines and travel recommendations for the prevention and treatment of malaria in different parts of the world. Discuss the most recent information with your doctor before traveling to areas where malaria occurs. This medication is also used to treat certain auto-immune diseases (lupus, rheumatoid arthritis). It belongs to a class of medications known as disease-modifying antirheumatic drugs (DMARDs). It can reduce skin problems in lupus and prevent swelling/pain in arthritis. Hydroxychloroquine is not recommended for coronavirus infection, also known as COVID-19, unless you are enrolled in a study. Talk to your doctor about the risks and benefits.

For medical billing and reimbursement, this package follows the 11-digit CMS format: 42291032018. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 180 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.